PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|February 16, 2024
EMA and HMA Launch Real-Word Data Catalogues
Author(s)Susan Haigney
Two public electronic catalogues will be available for real-world data sources and for real-world data studies.
Advertisement
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) announced on Feb. 15, 2024 that they have launched two public electronic catalogues for real-word data (RWD). The RWD catalogues will help regulators, researchers, and pharmaceutical companies identify suitable data sources for research and assessment of study protocols and results.
Created to promote transparency, encourage good practices, and build trust in RWD, the catalogues build on former databases developed by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). The RWD sources catalogue replaces the ENCePP Resources Database. The RWD studies catalogue replaces the European Union electronic register of post-authorization studies. The ENCePP website has been renewed. Data sources, centers, and networks have migrated to the new catalogues; however, some content will remain on the renewed ENCePP website.
Improvements over the previous databases have been included in the new catalogues. An agreed set of metadata have been used to describe and connect data sources to studies, based on a list of metadata published by the HMA-EMA Big Data Steering group in May 2022. Functionalities have been implemented such as a wider set of metadata, enhanced view, and export and data submissions.
“The publication of the RWD catalogues brings the European medicines regulatory network closer to more data-driven regulation. Improving discoverability of data is one of the priorities set in the HMA-EMA joint Big Data Task Force final report (phase two), reflected in the European medicines agencies network strategy to 2025 and implemented through the joint HMA-EMA Big Data Steering Group workplan. Ultimately, these developments will help European patients receive better medicines faster and promote safe and effective use of the medicines on the market,” EMA stated in a press release.
A
Source:
Advertisement
Related to this article
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
AI can turn medical device risk management into a continuous signal.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Lessons For AI Governance in Quality Systems
5